Current role of pharmacogenomics in cardiovascular medicine

Current Treatment Options in Cardiovascular Medicine

Volumn 13, Issue 4, 2011, Pages 302-312

  Musunuru, Kiran ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; TICAGRELOR; WARFARIN;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; COST EFFECTIVENESS ANALYSIS; CYP2C19 GENE; CYP2C9 GENE; DNA POLYMORPHISM; DRUG RESPONSE; GENE; GENETIC ASSOCIATION; HUMAN; INTERMETHOD COMPARISON; KINESIN LIKE FAMILY 6 GENE; PATIENT IDENTIFICATION; PATIENT SELECTION; PHARMACOGENOMICS; REGULATOR GENE; THROMBOEMBOLISM; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1 GENE;

EID: 80051673120     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-011-0129-6     Document Type: Article

References (39)

1. M Wadelius LY Chen N Eriksson, et al. 2007 Association of warfarin dose with genes involved in its action and metabolism Hum Genet 121 23 34 17048007 10.1007/s00439-006-0260-8 1:CAS:528:DC%2BD2sXhsFCgs78%3D (Pubitemid 46421137)
2. BF Gage C Eby JA Johnson, et al. 2008 Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin Clin Pharmacol Ther 84 326 331 18305455 10.1038/clpt.2008.10 1:CAS:528:DC%2BD1cXhtVShtr7F
3. International Warfarin Pharmacogenetics Consortium TE Klein RB Altman, et al. 2009 Estimation of the warfarin dose with clinical and pharmacogenetic data N Engl J Med 360 753 764 19228618 10.1056/NEJMoa0809329
4. MD Caldwell T Awad JA Johnson, et al. 2008 CYP4F2 genetic variant alters required warfarin dose Blood 111 4106 4112 18250228 10.1182/blood-2007-11-122010 1:CAS:528:DC%2BD1cXkvFeis7g%3D
5. M Wadelius LY Chen JD Lindh, et al. 2009 The largest prospective warfarin-treated cohort supports genetic forecasting Blood 113 784 792 18574025 10.1182/blood-2008-04-149070 1:CAS:528:DC%2BD1MXhtlGhsbc%3D
6. JL Anderson BD Horne SM Stevens, et al. 2007 Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation Circulation 116 2563 2570 17989110 10.1161/CIRCULATIONAHA.107. 737312 1:CAS:528:DC%2BD2sXhtlagsb3F (Pubitemid 350179221)
7. Y Caraco S Blotnick M Muszkat 2008 CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study Clin Pharmacol Ther 83 460 470 17851566 10.1038/sj.clpt.6100316 1:CAS:528:DC%2BD1cXitlGnsbs%3D (Pubitemid 351272635)
8. MH Eckman J Rosand SM Greenberg BF Gage 2009 Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation Ann Intern Med 150 73 83 19153410
9. SW Huang HS Chen XQ Wang, et al. 2009 Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients Pharmacogenet Genomics 19 226 234 19177029 10.1097/FPC. 0b013e328326e0c7 1:CAS:528:DC%2BD1MXjsVWqsbk%3D
10. RS Epstein TP Moyer RE Aubert, et al. 2010 Warfarin genotyping reduces hospitalization rates: results from the MM-WES (Medco-Mayo Warfarin Effectiveness Study) J Am Coll Cardiol 55 2804 2812 20381283 10.1016/j.jacc.2010.03.009 1:CAS:528:DC%2BC3cXps1ansLo%3D This community-based study demonstrated that genotyping of patients started on warfarin reduced the risk of hospitalization over the next 60 days.
11. B French J Joo NL Geller, et al. 2010 Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial Trials 11 108 21083927
12. JL Anderson CD Adams EM Antman, et al. 2007 ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine Circulation 11 e148 e304
13. FG Kushner M Hand SC Smith Jr, et al. 2009 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 120 2271 2306 19923169 10.1161/CIRCULATIONAHA.109.192663
14. PA Gurbel KP Bliden BL Hiatt CM O'Connor 2003 Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 107 2908 2913 12796140 10.1161/01.CIR. 0000072771.11429.83 (Pubitemid 36736631)
15. DJ Angiolillo A Fernandez-Ortiz E Bernardo, et al. 2007 Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives J Am Coll Cardiol 49 1505 1516 17418288 10.1016/j.jacc.2006.11.044 1:CAS:528:DC%2BD2sXjvFGgt7s%3D (Pubitemid 46517957)
16. JS Hulot A Bura E Villard, et al. 2006 Cytochrome P450 2 C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects Blood 108 2244 2247 16772608 10.1182/blood-2006-04-013052 1:CAS:528:DC%2BD28XhtVCgur7I (Pubitemid 44497506)
17. JL Mega SL Close SD Wiviott, et al. 2009 Cytochrome P-450 polymorphisms and response to clopidogrel N Engl J Med 360 354 362 19106084 10.1056/NEJMoa0809171 1:CAS:528:DC%2BD1MXhtVSlsbs%3D
18. T Simon C Verstuyft M Mary-Krause, et al. 2009 Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 363 375 19106083 10.1056/NEJMoa0808227 1:CAS:528:DC%2BD1MXhtVSlsbY%3D
19. JP Collet JS Hulot A Pena, et al. 2009 Cytochrome P450 2 C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study Lancet 373 309 317 19108880 10.1016/S0140-6736(08)61845-0 1:CAS:528:DC%2BD1MXhtVaqtrY%3D
20. G Paré SR Mehta S Yusuf, et al. 2010 Effects of CYP2C19 genotype on outcomes of clopidogrel treatment N Engl J Med 363 1704 1714 20979470 10.1056/NEJMoa1008410 This analysis of genetic data from two placebo-controlled clinical trials with lower-risk patients found no difference in relative cardiovascular risk reduction with clopidogrel between carriers and non-carriers of reduced-function CYP2C19 alleles.
21. L Wallentin S James RF Storey, et al. 2010 Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial Lancet 376 1320 1328 20801498 10.1016/S0140-6736(10)61274-3 1:CAS:528: DC%2BC3cXht12ks7nM This study found no difference in relative cardiovascular risk reduction with ticagrelor compared to clopidogrel between carriers and non-carriers of reduced-function CYP2C19 alleles. It also suggested that any difference in cardiovascular protection by clopidogrel between carriers and non-carriers is more relevant to the acute setting rather than to chronic use of the medication.
22. JL Mega T Simon JP Collet, et al. 2010 Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis JAMA 304 1821 1830 20978260 10.1001/jama.2010.1543 1:CAS:528:DC%2BC3cXhtlGqurbO The meta-analysis of nine studies with higher-risk patients on clopidogrel documented a tripling of risk for stent thrombosis in carriers of reduced-function CYP2C19 alleles.
23. R Blindt K Stellbrink A de Taeye, et al. 2007 The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis Thromb Haemost 98 1329 1334 18064332 1:CAS:528:DC%2BD1cXnsV2nug%3D%3D (Pubitemid 350239106)
24. NS Abraham MA Hlatky EM Antman, et al. 2010 ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents Circulation 122 2619 2633 21060077 10.1161/CIR.0b013e318202f701
25. SEARCH Collaborative Group E Link S Parish, et al. 2008 SLCO1B1 variants and statin-induced myopathy-a genomewide study N Engl J Med 359 789 799 18650507 10.1056/NEJMoa0801936 1:CAS:528:DC%2BD1cXhtVShtbnF
26. D Voora SH Shah I Spasojevic, et al. 2009 The SLCO1B1*5 genetic variant is associated with statin-induced side effects J Am Coll Cardiol 54 1609 1616 19833260 10.1016/j.jacc.2009.04.053 1:CAS:528:DC%2BD1MXhsVGnu77E
27. AC Morrison LA Bare LE Chambless, et al. 2007 Prediction of coronary heart disease risk using a genetic risk score: the Atherosclerosis Risk in Communities study Am J Epidemiol 166 28 35 17443022 10.1093/aje/kwm060 (Pubitemid 47234300)
28. D Shiffman ES O'Meara LA Bare, et al. 2008 Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study Arterioscler Thromb Vasc Biol 28 173 179 17975119 10.1161/ATVBAHA.107.153981 1:CAS:528:DC%2BD2sXhsVeiu7fN
29. OA Iakoubova CH Tong CM Rowland, et al. 2008 Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials J Am Coll Cardiol 51 435 443 18222353 10.1016/j.jacc.2007.05.057 1:CAS:528: DC%2BD1cXhtV2nt7c%3D
30. D Shiffman DI Chasman RY Zee, et al. 2008 A kinesin family member 6 variant is associated with coronary heart disease in the Women's Health Study J Am Coll Cardiol 51 444 448 18222354 10.1016/j.jacc.2007.09.044 1:CAS:528:DC%2BD1cXhtV2ntL4%3D
31. OA Iakoubova MS Sabatine CM Rowland, et al. 2008 Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study J Am Coll Cardiol 51 449 455 18222355 10.1016/j.jacc.2007.10.017 1:CAS:528:DC%2BD1cXhtV2ntL8%3D
32. AF Stewart S Dandona L Chen, et al. 2009 Kinesin family member 6 variant Trp719Arg does not associate with angiographically defined coronary artery disease in the Ottawa Heart Genomics Study J Am Coll Cardiol 53 1471 1472 19371834 10.1016/j.jacc.2008.12.051 1:CAS:528:DC%2BD1MXkslGqtb0%3D
33. Y Li OA Iakoubova D Shiffman, et al. 2010 KIF6 polymorphism as a predictor of risk of coronary events and of clinical event reduction by statin therapy Am J Cardiol 106 994 998 20854963 10.1016/j.amjcard.2010.05.033 1:CAS:528:DC%2BC3cXhtFOntbjF A meta-analysis of the data available at the time, from seven cohort studies, suggested an association between the KIF6 W719R variant and disease.
34. TL Assimes H Hólm S Kathiresan, et al. 2010 Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies J Am Coll Cardiol 56 1552 1563 20933357 10.1016/j.jacc.2010.06.022 1:CAS:528:DC%2BC3cXhsF2htL3N This case-control study with 17,000 cases of coronary disease and almost 40,000 controls found no evidence for an association between the KIF6 W719R variant and disease.
35. Myocardial Infarction Genetics Consortium 2009 Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants Nat Genet 41 334 341 10.1038/ng.327
36. DA Trégouët IR König J Erdmann, et al. 2009 Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease Nat Genet 41 283 285 19198611 10.1038/ng.314
37. OA Iakoubova M Robertson CH Tong, et al. 2010 KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study Eur J Cardiovasc Prev Rehabil 17 455 461 20215968 10.1097/HJR. 0b013e328336a0dd
38. JC Hopewell S Parish R Clarke, et al. 2011 No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the Heart Protection Study J Am Coll Cardiol 10.1016/j.jacc.2011.02.015 21458191 The analysis of genetic data from more than 18,000 participants in the Heart Protection Study found no significant difference in the benefit conferred by statin use in carriers of the KIF6 W719R variant compared to non-carriers.
39. EJ Topol SB Damani 2010 The KIF6 collapse J Am Coll Cardiol 56 1564 1566 20888161 10.1016/j.jacc.2010.06.023